Diel Peter
Orthopädie Sonnenhof, Bern
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Diel Peter as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:58 UTC. Open this list on ClinicalTrials.gov
- N/ANCT05238740 · Comparison of Radiographic Fusion Rate and Clinical Outcome of ALIF and XLIF Performed With Either Recombinant Human Bone Morphogenetic Protein-2 or ViviGen®Lindenhofgruppe AG · recruiting · Spondylosis, Spondylolisthesis, Degenerative Disc Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:58 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.Lancet Infect Dis · 202520 citationsRCR 6.9
- Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.Lancet Infect Dis · 202519 citationsRCR 6.1
- Subcutaneous lidocaine delivered by jet-injector for pain control before IV catheterization in the ED: the patients' perception and preference.Am J Emerg Med · 200211 citationsRCR 0.5
- Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion.Circ Cardiovasc Qual Outcomes · 20195 citationsRCR 0.4
- Role of polymerase chain reaction in the diagnosis of Trichomonas vaginalis infection in human immunodeficiency virus-infected individuals from India (South).Indian J Dermatol Venereol Leprol · 20124 citationsRCR 0.2
- Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB.J Antimicrob Chemother · 20253 citationsRCR 1.0